142012-65-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(Trifluoromethyl)-DL-phenylglycine is used as an intermediate for the synthesis of PPARγ/δ dual agonists. These agonists are significant in the development of treatments for metabolic disorders, such as diabetes and obesity, due to their role in regulating cellular differentiation and energy homeostasis.
Additionally, 4-(Trifluoromethyl)-DL-phenylglycine is used in preparing heterocyclic xanthine derivatives, which are highly potent and selective human A2B adenosine receptor antagonists. These antagonists have potential therapeutic applications in treating various conditions, including asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory diseases.

InChI:InChI=1/C9H8F3NO2/c10-9(11,12)6-3-1-5(2-4-6)7(13)8(14)15/h1-4,7H,13H2,(H,14,15)

Upstream product

• 79478-02-7 4-(trifluoromethyl)phenylglyoxylic acid 

Downstream Products

• 142044-52-8 2-Fluoro-2-(4-trifluoromethylphenyl)acetic acid 
• 390815-48-2 methyl 2-amino-2-[4-(trifluoromethyl)phenyl]acetate hydrochloride 
• 473416-36-3 2-amino-2-(4-(trifluoromethyl)phenyl)ethan-1-ol 
• 439088-62-7 methyl 2-amino-2-(4-(trifluoromethyl)phenyl)acetate 

Relevant academic research and scientific papers

CATALYST COMPOUNDS

The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions.

Primary amines by transfer hydrogenative reductive amination of ketones by using cyclometalated IrIII catalysts

Cyclometalated iridium complexes are found to be versatile catalysts for the direct reductive amination (DRA) of carbonyls to give primary amines under transfer-hydrogenation conditions with ammonium formate as both the nitrogen and hydrogen source. These complexes are easy to synthesise and their ligands can be easily tuned. The activity and chemoselectivity of the catalyst towards primary amines is excellent, with a substrate to catalyst ratio (S/C) of 1000 being feasible. Both aromatic and aliphatic primary amines were obtained in high yields. Moreover, a first example of homogeneously catalysed transfer-hydrogenative DRA has been realised for β-keto ethers, leading to the corresponding β-amino ethers. In addition, non-natural α-amino acids could also be obtained in excellent yields with this method. Reduce the work! A broad range of ketones have been successfully aminated to afford primary amines under transfer-hydrogenation conditions by using ammonium formate as the amine source and 0.1 mol % of a cyclometalated IrIII catalyst (see scheme). Copyright

CATALYST COMPOUNDS

The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions.